Unknown PHASE2 INTERVENTIONAL 1-arm NCT03199677

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Sponsor: Chinese Academy of Medical Sciences

Conditions Refractory Cancer

Interventions Apatinib

Updated 8 times since 2017 Last updated: Jun 29, 2017 Started: Jul 1, 2017 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Refractory Cancer and is currently ongoing. Chinese Academy of Medical Sciences leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Oct 2023 — Jul 2024 [monthly]

Unknown Status PHASE2
Dec 2022 — Oct 2023 [monthly]

Unknown Status PHASE2
Jan 2021 — Dec 2022 [monthly]

Unknown Status PHASE2

▶ Show 3 earlier versions

Jul 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Jul 2019 [monthly]

Recruiting PHASE2
Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China